{"title":"Epidemiological Characteristics of Hepatitis B Positive Patients in Oman between 2009 and 2019: A Retrospective Cohort Study","authors":"S. Awaidy","doi":"10.33552/ajgh.2021.03.000553","DOIUrl":"https://doi.org/10.33552/ajgh.2021.03.000553","url":null,"abstract":"The prevalence of chronic hepatitis in Oman was estimated to 2-7% prior to the introduction of vaccination. However, HBV remains a major concern among unvaccinated individuals, especially older adults. Objective: The study aim is to describe the epidemiological characteristics of HBV positive patients at a specialized liver clinic at the Armed Forces Hospital, between January 2009 and December 2019. A retrospective cohort study was undertaken, and secondary data were obtained from electronic medical records. Results: 593 patients with positive HBV serology were identified. Fifty-nine percent of patients were male, with a mean age of 42 years (SD: 10.05) compared to females (43 years, SD: 10.70). Eighty-five percent (492/580) of the patients were treatment naïve. Eighty-eight percent showed detectable HBV viremia. The median level of HBV DNA among chronic hepatitis BV patients who are HBeAg-positive was significantly higher: 1 884 847 IU/ml (IQR: 81662-486924145), as compared to the rest of chronic hepatitis BV patients: 339 IU/ml (IQR: 33.5-3366). Elevated ALT (≥ 40 IU/ ml) was found in 29% of the patients. liver abnormalities were detected by ultrasound in 28% (165) of patients. Treatment was introduced in 15% of patients. Conclusion: The majority of HBV patients were seronegative for HB-Ag and were born before the vaccination era. Therefore, these patients with hepatitis B in dormancy do not need treatment, but regular monitoring and follow-up.","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42325272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Use of Silimarin in the Treatment of Non-Alcoholic Fatty Liver Disease (Nafld)","authors":"Sander Bq","doi":"10.33552/ajgh.2021.03.000552","DOIUrl":"https://doi.org/10.33552/ajgh.2021.03.000552","url":null,"abstract":"Non-alcoholic hepatic steatosis is characterized by steatosis and necroinflammation, with or without centrilobular fibrosis [1], in cases where the deposit of lipids in hepatocytes exceeds 5% of the total weight of the liver and there is no other causes of hepatic involvement [2]. Therefore, in its diagnosis it is necessary to exclude viral hepatitis, use of drugs that promote parenchymal alterations, autoimmune hepatitis, hemochromatosis, Wilson’s disease, or significant alcohol consumption above 30 g daily for men, and 20 g daily for women [3]. The main risk factors for its development are the components of the metabolic syndrome, weight gain, insulin resistance, hypertension, and hyperlipidemia [1]. These risk factors suggest reasons for the increased prevalence of nonalcoholic hepatic steatosis in the world, probably as a result of changes in lifestyle and eating habits, with increasing consumption of carbohydrates, also contributing to the evolution of diagnostic methods for the disease. This prevalence, although the numbers may vary between authors, is currently estimated at 20% to 40% in the world population, and this high incidence has become a source of concern for health professionals [3-6].","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46695135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Aftermath Pandemic Challenges for the Cancer Service Provision, The Need for A Fitting Strategy: A Standpoint from the UK","authors":"Y. Viswanath","doi":"10.33552/ajgh.2021.03.000551","DOIUrl":"https://doi.org/10.33552/ajgh.2021.03.000551","url":null,"abstract":"Soon after the 1st lockdown was imposed in the UK on March 27, 2020, all elective activity surgical and endoscopic stopped in James Cook University Hospital, Cleveland County in North England. It was almost a standstill due to fear of the unknown and senior upper GI oncology surgeon thinking how one could not stop cancer-related care, especially extensive major cancer surgeries such as esophagectomy and gastrectomy. Approach with common sense, untold braveness with available guidance and safety kit, surgeries continued despite the risk to the operating surgical team and the patient. The UK health ministry’s announcement was candid and stated the cancer care should continue, and one must not deny timely access to the treatment. Furthermore, potential patients’ reluctance to attend hospitals, reduced access to primary care, delayed referrals, and a few other factors impacted deferred diagnosis. The estimated loss could amount to 60,000 life-years plus in the next decade in the UK [1].","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45416930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New Paradigms in the Treatment of Metastatic Hepatocarcinoma: Case Report","authors":"E. Melo","doi":"10.33552/ajgh.2021.02.000550","DOIUrl":"https://doi.org/10.33552/ajgh.2021.02.000550","url":null,"abstract":"of The results of the phase III study, IMbrave 150, which compared atezolizumab plus bevacizumab versus sorafenib, represented an important advance in the first-line treatment. We report a clinical case of a 78-year-old patient with metastatic hepatocarcinoma, who underwent first-line treatment with the combination of atezolizumab and bevacizumab. After 3 treatment cycles, there was a complete response in the lung and a partial response in the liver, opening the discussion about the possibility of considering at some point the local treatment of the liver in the face of tumor downstaging.","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69448739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Crohn’s Disease: A Curable Disease Held Hostage?","authors":"E. Melo","doi":"10.33552/ajgh.2020.02.000550","DOIUrl":"https://doi.org/10.33552/ajgh.2020.02.000550","url":null,"abstract":"","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44785586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ramzan for Patients with Chronic Liver Disease","authors":"Z. Majid","doi":"10.33552/ajgh.2020.02.000548","DOIUrl":"https://doi.org/10.33552/ajgh.2020.02.000548","url":null,"abstract":"With the holy month of Ramzan fast approaching us, Muslim’s from all around the world would be engaged in various religious activities including fasting. Ramzan is the 9th month of the Islamic calendar and during which fasting is obligatory for all muslims. During a fast a Muslim not only abstains themselves from food and water but also from smoking and oral medications [1]. A typical fast last around 12-18 hours [2] At present the impact of fasting on patients with chronic liver disease regardless of its etiologic is scarce. Here we wish to highlight the effects of fasting in the month of ramzan and the precautionary measures that need to be taken in this month in patients diagnosed with chronic liver disease (regardless of its etiology). Cirrhotics are particularly at risk of protein energy malnutrition (PEM), upper gastrointestinal bleed, worsening of their liver functions along with encephalopathy and discontinuation of their medications during fasting [3]. Along with this, fasting in the tropics or during the summer season may place these patients at risk of renal dysfunction [3]. Generally, it is recommended that patients having Child Pugh score C (CPS) cirrhosis should avoid fasting [3].","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46510917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recurrence of Upper Gastrointestinal Hemorrhage in Sclerotherapy X Elastic Ligature: Systematic Review","authors":"Sander Bq","doi":"10.33552/ajgh.2020.02.000547","DOIUrl":"https://doi.org/10.33552/ajgh.2020.02.000547","url":null,"abstract":"s: To compare, through a systematic review, the recurrence of upper digestive hemorrhage in the techniques of sclerotherapy and The most relevant studies in the MedLine, Bireme and Scielo databases were analyzed. The search strategy used the following keyword combinations: (“High Digestive Hemorrhage, Sclerotherapy, Elastic Bandage”). Results: There were 9 studies selected from the crossword of the keywords, and of these, only 6 were used in the studies after applying the Randomized Controlled Trial and Clinical Trials filters. Conclusion: There is no definite consensus on which technique - sclerotherapy or elastic ligation - could be associated with a lower risk of recurrence in cases involving upper gastrointestinal bleeding. The literature shows advantages both in the technique of sclerotherapy and in the technique of elastic ligation, and in general, it is nowadays observed that the technique considered gold standard for these cases is the technique of elastic ligation, although many professionals still opt for sclerotherapy, especially in surgical intervention in pediatric patients.","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42906054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Two Nobel Prizes that Both Fight Starvation, Helicobacter Pylori and WFP","authors":"T. Midtvedt","doi":"10.33552/ajgh.2021.02.000546","DOIUrl":"https://doi.org/10.33552/ajgh.2021.02.000546","url":null,"abstract":"In 2020 the Nobel Peace prize was awarded to World Food Program (WFP) due to their important job in distributing food and fighting starvation all over the world. Fifteen years earlier the Nobel Prize in Physiology or Medicine was awarded for the discovery of the bacterium Helicobacter pylori. This bacterium – in its own way actually also helps fight starvation. In 2018 it was estimated that across the world 821 million people were going hungry -124 million acutely so [1]. In order to reduce starvation and treat malnutrition WFP for many years have delivered so called food baskets. The actual size and composition of the food basket is closely tailored to local preferences, demographic profile, climate conditions, local coping capacity and existing levels of malnutrition and disease [2]. In 1982 Robin Warren and Barry J. Marshall unexpectedly discovered that inflammation in the stomach (gastritis) as well as ulceration of the stomach or duodenum (peptic ulcer disease) could be the result of an infection caused by a bacterium. In 2005 they jointly were awarded the Nobel Prize in Physiology or Medicine. The infection could be treated by antibiotics. The bacterium was named Helicobacter pylori (H. pylori).","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46627130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fodmap’s Restricted Diet in Patients with Irritable Gut Syndrome: A Systematic Review","authors":"Sander Bq","doi":"10.33552/AJGH.2020.02.000545","DOIUrl":"https://doi.org/10.33552/AJGH.2020.02.000545","url":null,"abstract":"To verify the The most and were (National and SciELO as In order to select the studies with the greatest scientific we and review studies. The search strategy the following keywords: “irritable bowel syndrome” and “FODMAP’s restricted diet”. To identify the designs of the studies, the following terms were used: clinical trials. Results: Initially, 117 studies were identified involving irritable bowel syndrome and the Foodmap diet. However, after applying the Clinical Trials filters, 10 studies were found. After reading the articles found and excluding them from the abstracts, 5 articles were selected involving the theme for analysis and inclusion in the scope of this review. Conclusion: The restricted diet in FODMAPs proved to be very effective in improving general and specific symptoms of irritable bowel syndrome, especially abdominal pain, bloating and diarrhea. compared to the positive control and may be better tolerated in individuals with IBS. Further research should be con-ducted to better understand the GI tolerance of low FODMAP ONS in individuals with IBS.","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44308487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Invasive Cancer of the Colon with Gastric Metastasis","authors":"A. Gligorievski","doi":"10.33552/AJGH.2020.02.000544","DOIUrl":"https://doi.org/10.33552/AJGH.2020.02.000544","url":null,"abstract":"We present case of metastatic from cancer. Computed tomography (CT) indicated primary colon cancer, but also revealed the presence of cancer in the region of the gastric greater curvature and gastric antrum. With the progression of primary cancer and the creation of an extraluminal tumor mass, the process progresses in the manner that the primary transversal colon tumor merges into the metastatic deposit located in the stomach. The patient underwent subtotal gastrectomy and D2 lymphadenectomy, as well as partial resection of the transversal colon, thus the tumor mass of the stomach and the one in the transversal colon being removed in a single act. Pathohistological analysis of the tumor mass and immunohistochemical tests revealed a primary neoplastic infiltrative process in the colon metastasizing into the stomach.","PeriodicalId":72038,"journal":{"name":"Academic journal of gastroenterology & hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43507050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}